Sensei Biotherapeutics Inc. Announces Advisory Board Appointments
May 05, 2021 at 08:52 am EDT
Share
Sensei Biotherapeutics Inc. announced the appointments of Maura Gillison, M.D., Ph.D., Professor of Medicine, Thoracic/Head and Neck Medical Oncology at MD Anderson Cancer Center, and Richard Ulevitch, Ph.D., Professor of Immunology and Chairman Emeritus at The Scripps Research Institute, to its Immuno-Oncology Advisory Board. Dr. Maura Gillison, widely known as an expert in head and neck cancers, molecular epidemiology and virology, is a Professor of Medicine in the Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center. Included in more than 200 scientific publications, her research expertise has led to developments related to the causation of head and neck cancers from human papillomavirus (HPV) infection and shifts in concepts for risk, diagnosis and therapeutic approaches to treat those cancers. She is a member of the National Academy of Medicine and also a CPRIT scholar. Dr. Richard Ulevitch, Professor of Immunology and Chairman Emeritus of the Department of Immunology at The Scripps Research Institute brings experience in business development from his involvement in life science investment funds, as well as deep scientific knowledge related to innate immunity. Dr. Ulevitch is currently a Venture Partner Emeritus at 5AM Ventures, which he joined in 2002.
Sensei Biotherapeutics, Inc. is a clinical-stage immuno-oncology company, which is focused on the discovery and development of therapeutics for cancer patients. Through its Tumor Microenvironment Activated biologics (TMAb) platform, the Company develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment to unleash T cells against tumors. Its lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation checkpoint selectively within the low pH tumor microenvironment. It is also developing SNS-102, a conditionally active monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4); SNS-103, a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), CD39; and SNS-201, a conditionally active VISTAxCD28 bispecific antibody.
SENSEI BIOTHERAPEUTICS, INC. 
